Park Capital Management LLC WI Buys New Position in Johnson & Johnson (NYSE:JNJ)

Park Capital Management LLC WI purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 6,240 shares of the company’s stock, valued at approximately $902,000. Johnson & Johnson comprises approximately 1.1% of Park Capital Management LLC WI’s holdings, making the stock its 18th biggest holding.

Several other hedge funds also recently modified their holdings of JNJ. Powers Advisory Group LLC lifted its position in shares of Johnson & Johnson by 0.6% during the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock worth $1,538,000 after purchasing an additional 61 shares in the last quarter. Knuff & Co LLC lifted its holdings in Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after buying an additional 64 shares in the last quarter. Vertex Planning Partners LLC boosted its position in Johnson & Johnson by 1.3% in the 3rd quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock valued at $844,000 after buying an additional 65 shares during the last quarter. Freedom Day Solutions LLC increased its stake in shares of Johnson & Johnson by 1.1% in the 3rd quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company’s stock valued at $1,016,000 after buying an additional 66 shares during the period. Finally, Traphagen Investment Advisors LLC raised its position in shares of Johnson & Johnson by 0.6% during the third quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company’s stock worth $1,699,000 after acquiring an additional 67 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on JNJ. Morgan Stanley lowered their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 23rd. Bank of America lowered their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Barclays increased their price target on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 28th. Finally, Citigroup dropped their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $156.20 on Friday. The company has a fifty day moving average price of $147.87 and a 200 day moving average price of $156.00. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The firm has a market cap of $376.08 billion, a PE ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter last year, the firm earned $2.29 EPS. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.18%. Johnson & Johnson’s payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.